Epimacular Membrane Treatment & Management

  • Author: Kean Theng Oh, MD; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Feb 16, 2012
 

Surgical Care

Isolate EMM as the main cause of a patient's visual impairment prior to planning a corrective procedure. Evaluate the patient carefully to rule out other pathologic conditions, such as macular holes, subfoveal choroidal neovascular membranes, cystoid macular edema, or retinal vascular occlusive disease, that may mimic the appearance of a true membrane.

Surgical treatment of EMM is usually not an emergent procedure. Only when there is macular edema does it become a more urgent procedure.

Several surgical techniques exist for the treatment of EMM. However, 3 basic stages of treatment exist.

  • Vitrectomy
    • Pars plana vitrectomy is performed to excise the posterior and central vitreous in phakic patients and the remainder of the anterior vitreous in aphakic and pseudophakic patients. This step is especially important in cases where marked adherence of the vitreous to the macula is present.
    • Lately, questions have been raised regarding the need for vitrectomy in EMM peeling, especially in those cases where no significant PVR exists.
    • The main advantages of doing a vitrectomy are the prevention of vitreous contraction and elimination of vitreous traction on the macula. In addition, removal of the vitreous is believed by many to increase the safety of the mechanical aspects of the membrane removal.
    • The main disadvantages of vitrectomy include cataractogenesis and increased possibility of creating iatrogenic retinal breaks. Vitrectomy has been shown to increase the rate of cataract formation through unclear mechanisms.
    • Studies have shown that a 3-fold increase in the rate of significant cataract formation exists in patients that have undergone vitrectomy after a follow-up period of only 6 months.
    • Some surgeons feel that the effectiveness of membrane peeling is negated significantly by the cataract formation such that they have foregone vitrectomy in selected cases, opting to perform no-infusion/no-vitrectomy membrane peelings. The main disadvantage of this technique is the persistence of floaters postoperatively, which may be very bothersome to some patients. Furthermore, some surgeons have seen no significant difference in either cataractogenesis or development of retinal breaks/detachments in their series comparing vitrectomizing and nonvitrectomizing techniques.
    • While the vitrectomy can be performed using the standard 20-gauge system, surgeons are also using smaller gauge vitrectomy systems (eg, 23 gauge, 25 gauge) for surgical management of EMM.[5, 6] These systems are transconjunctival with the potential to create self-sealing wounds. Complications appear low while affording the potential for more rapid surgical and visual recovery.
  • Epiretinal membrane peeling
    • From the time Machamer developed the concept of membrane peeling in the mid 1970s, several variations and refinements in both technique and instrumentation have been developed.
    • This procedure basically involves identifying the outer edge of the membrane and creating a dissection plane with the use of a blunt-tipped pick or a bent needle.
    • Once the edge of the membrane is seen, it may be gently lifted off the retinal surface with the use of a pick or fine forceps.
    • The membrane should be lifted in a tangential rather than an anteroposterior fashion so as not to pull on the underlying retina and create tears. This maneuver is relatively straightforward if the edge of the membrane is visible.
    • Charles developed a maneuver that approaches the membrane from inside out in cases where the edge is difficult to identify.[7] It involves creating a slit on the thickest part of the membrane with a straight microvitreoretinal blade and using this opening as the edge with which to start the peeling. The peeling is performed moving the forceps in a circular fashion similar to capsulorrhexis. The freed membrane should be removed either by pulling it out with the forceps through the sclerotomy or by using the vitreous cutter.
  • Internal limiting membrane (ILM) peeling
    • Removal of the ILM at the time of EMM peeling is a current controversy.
    • Vital stains, such as indocyanine green (ICG) dye and Trypan blue dye, have been used to assist ILM and EMM peeling. Dyes that stain the ILM highlight foci of EMM and potentially reduce the risk of recurrence or the persistence of symptoms.
    • Similar to its use in macular hole surgery, the use of ICG has proponents and detractors on the basis of its potential toxic effects. Haritoglou et al suggested that ICG-assisted ILM peeling may adversely affect the functional outcome of surgery for EMM.[8, 9]
    • Hillenkamp et al prospectively evaluated the effect of ICG dye in the setting of EMM surgery.[10] No difference or evidence of ICG toxicity was observed. Both visual function and macular morphology improved in patients with and without ICG dye use.
    • However, Garweg et al suggested that ILM peeling with ICG dye, but not with trypan blue dye, may result in loss of the central visual field over time.[11] No difference in visual acuity was noted. This study suggests that the ICG dye, not necessarily the ILM peeling, may have an adverse effect following EMM surgery.
  • Management of retinal breaks
    • Once the membrane is removed, it is imperative for the surgeon to look for any breaks in the retina, both in the posterior pole and in the periphery.
    • Any maneuvers completed to remove the membranes, no matter how elegant, become irrelevant if the retina detaches because of missed breaks.
    • Careful scleral depression of the anterior retina combined with indirect ophthalmoscopy should be performed to detect breaks in the periphery.
    • Breaks without subretinal fluid accumulation can be treated by laser retinopexy or cryoretinopexy.
    • The presence of significant amounts of subretinal fluid necessitates internal drainage under air, retinopexy, and gas tamponade.
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Kean Theng Oh, MD  Consulting Staff, Associated Retinal Consultants, PC

Kean Theng Oh, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Coauthor(s)

Bradley M Hughes, MD  Assistant Professor, Department of Ophthalmology, Retina and Vitreous Service, University of Arkansas for Medical Sciences

Bradley M Hughes, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Ophthalmology

Disclosure: Nothing to disclose.

John H Drouilhet, MD, FACS  Clinical Professor, Department of Surgery, Section of Ophthalmology, University of Hawaii, John A Burns School of Medicine

John H Drouilhet, MD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and American Medical Association

Disclosure: Nothing to disclose.

Specialty Editor Board

V Al Pakalnis, MD, PhD  Professor of Ophthalmology, University of South Carolina School of Medicine; Chief of Ophthalmology, Dorn Veterans Affairs Medical Center

V Al Pakalnis, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and South Carolina Medical Association

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Steve Charles, MD  Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine; Adjunct Professor of Ophthalmology, Columbia College of Physicians and Surgeons; Clinical Professor Ophthalmology, Chinese University of Hong Kong

Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society

Disclosure: Alcon Laboratories Consulting fee Consulting; OptiMedica Ownership interest Other; Topcon Medical Lasers Consulting fee Consulting

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

Additional Contributors

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Sherman O Valero, MD, to the development and writing of this article.

References
  1. Chang LK, Fine HF, Spaide RF, et al. Ultrastructural correlation of spectral-domain optical coherence tomographic findings in vitreomacular traction syndrome. Am J Ophthalmol. Jul 2008;146(1):121-7. [Medline].

  2. Bovey EH, Uffer S. Tearing and folding of the retinal internal limiting membrane associated with macular epiretinal membrane. Retina. Mar 2008;28(3):433-40. [Medline].

  3. Karacorlu M, Ozdemir H, Senturk F, Karacorlu SA, Uysal O. Correlation of retinal sensitivity with visual acuity and macular thickness in eyes with idiopathic epimacular membrane. Int Ophthalmol. Jun 2010;30(3):285-90. [Medline].

  4. Gupta P, Sadun AA, Sebag J. Multifocal retinal contraction in macular pucker analyzed by combined optical coherence tomography/scanning laser ophthalmoscopy. Retina. Mar 2008;28(3):447-52. [Medline].

  5. Gupta OP, Ho AC, Kaiser PK, et al. Short-term outcomes of 23-gauge pars plana vitrectomy. Am J Ophthalmol. Aug 2008;146(2):193-197. [Medline].

  6. Gupta OP, Weichel ED, Regillo CD, et al. Postoperative complications associated with 25-gauge pars plana vitrectomy. Ophthalmic Surg Lasers Imaging. Jul-Aug 2007;38(4):270-5. [Medline].

  7. Charles S. Epimacular Membranes. In: Guyer DR, Yannuzzi LA, Chang S, et al. Retina-Vitreous-Macula. Vol 2. Philadelphia, Pa: WB Saunders Co; 1999:230-7.

  8. Haritoglou C, Gandorfer A, Gass CA, et al. The effect of indocyanine-green on functional outcome of macular pucker surgery. Am J Ophthalmol. Mar 2003;135(3):328-37. [Medline].

  9. Casparis H, Bovey EH. Surgical treatment of lamellar macular hole associated with epimacular membrane. Retina. Oct 2011;31(9):1783-90. [Medline].

  10. Hillenkamp J, Saikia P, Herrmann WA, et al. Surgical removal of idiopathic epiretinal membrane with or without the assistance of indocyanine green: a randomised controlled clinical trial. Graefes Arch Clin Exp Ophthalmol. Jul 2007;245(7):973-9. [Medline].

  11. Garweg JG, Bergstein D, Windisch B, et al. Recovery of visual field and acuity after removal of epiretinal and inner limiting membranes. Br J Ophthalmol. Feb 2008;92(2):220-4. [Medline].

  12. Gass JDM. Macular dysfunction caused by epiretinal membrane contraction. In: Stereoscopic Atlas of Macular Diseases: Diagnosis and Treatment. Vol 2. 4th ed. St. Louis, Mo: Mosby; 1997:938-950.

  13. Haritoglou C, Gandorfer A, Schaumberger M, et al. Trypan blue in macular pucker surgery: an evaluation of histology and functional outcome. Retina. Aug 2004;24(4):582-90. [Medline].

  14. Marghero RR. Epiretinal macular membranes. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol 2. Philadelphia, Pa: WB Saunders Co; 1994:919-925.

  15. McDonald HR, Schatz H, Johnson RN. Introduction to epiretinal membranes. In: Ryan SJ, ed. Retina. Vol 2. 2nd ed. St. Louis, Mo: Mosby; 1994:1819-1825.

  16. Russell SR, Crapotta JA. Macular epiretinal membranes. Ophthalmol Clin North Am. June 1993;6(2):239-45.

  17. Sjaarda RN, Michels RG. Macular pucker. In: Ryan SJ, ed. Retina. Vol 3. 2nd ed. St. Louis, Mo: Mosby; 1994:2301-2312.

  18. Ting FS, Kwok AK. Treatment of epiretinal membrane: an update. Hong Kong Med J. Dec 2005;11(6):496-502. [Medline].

  19. Wong JG, Sachdev N, Beaumont PE, et al. Visual outcomes following vitrectomy and peeling of epiretinal membrane. Clin Experiment Ophthalmol. Aug 2005;33(4):373-8. [Medline].

Previous
Next
 
Very dense epimacular membrane with associated macular distortion.
Grade 2 epimacular membrane causing striations in the retinal surface. Note the presence of a pseudohole.
Fluorescein angiogram demonstrating retinal vascular distortion. Note the leakage of the dye in the macular area, which represents secondary macular edema.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.